NOIANA bilateral simultánea tras inicio de semaglutida a dosis elevadas: comunicación de un caso

Q3 Medicine
V.M. Asensio-Sánchez, J. Rodríguez-Espinosa, S. Silva-Schultz, G. González-Fernández, S. Lallana-Serrano
{"title":"NOIANA bilateral simultánea tras inicio de semaglutida a dosis elevadas: comunicación de un caso","authors":"V.M. Asensio-Sánchez,&nbsp;J. Rodríguez-Espinosa,&nbsp;S. Silva-Schultz,&nbsp;G. González-Fernández,&nbsp;S. Lallana-Serrano","doi":"10.1016/j.oftal.2026.502490","DOIUrl":null,"url":null,"abstract":"<div><div>We report a case of simultaneous bilateral non-arteritic anterior ischemic optic neuropathy (NAION) in a 68-year-old man with poorly controlled type<!--> <!-->2 diabetes mellitus and significant hyperopia (+5<!--> <!-->diopters). Visual loss began 14<!--> <!-->days after initiating semaglutide at a relatively high dose (0.5<!--> <!-->mg/week), progressing to functional blindness within four weeks. Ophthalmologic examination revealed bilateral optic disc edema with hemorrhages, exudates, and subretinal fluid. Infectious and autoimmune causes were ruled out, and cerebrospinal fluid analysis was normal. Following the high dose of semaglutide, glycated hemoglobin decreased, although the magnitude and speed of this decline should be interpreted with caution, and the association between the drug and the optic nerve event must be considered purely temporal, with no evidence of direct causality. Despite drug discontinuation and corticosteroid treatment, visual loss persisted. The simultaneous bilateral presentation, rapid progression, and predisposing anatomical factors — crowded optic discs and possible scleral rigidity — highlight extreme vulnerability. This case illustrates a possible temporal association, representing one of the few such cases reported to date, and underscores the importance of baseline ophthalmic evaluation, close monitoring, and careful consideration of initial dosing in patients treated with GLP-1 receptor agonists.</div></div>","PeriodicalId":8348,"journal":{"name":"Archivos De La Sociedad Espanola De Oftalmologia","volume":"101 7","pages":"Article 502490"},"PeriodicalIF":0.0000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos De La Sociedad Espanola De Oftalmologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0365669126000286","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

We report a case of simultaneous bilateral non-arteritic anterior ischemic optic neuropathy (NAION) in a 68-year-old man with poorly controlled type 2 diabetes mellitus and significant hyperopia (+5 diopters). Visual loss began 14 days after initiating semaglutide at a relatively high dose (0.5 mg/week), progressing to functional blindness within four weeks. Ophthalmologic examination revealed bilateral optic disc edema with hemorrhages, exudates, and subretinal fluid. Infectious and autoimmune causes were ruled out, and cerebrospinal fluid analysis was normal. Following the high dose of semaglutide, glycated hemoglobin decreased, although the magnitude and speed of this decline should be interpreted with caution, and the association between the drug and the optic nerve event must be considered purely temporal, with no evidence of direct causality. Despite drug discontinuation and corticosteroid treatment, visual loss persisted. The simultaneous bilateral presentation, rapid progression, and predisposing anatomical factors — crowded optic discs and possible scleral rigidity — highlight extreme vulnerability. This case illustrates a possible temporal association, representing one of the few such cases reported to date, and underscores the importance of baseline ophthalmic evaluation, close monitoring, and careful consideration of initial dosing in patients treated with GLP-1 receptor agonists.
高剂量Semaglutide发病后双侧NOIANA并发病例:1例报告
我们报告一例同时双侧非动脉性前缺血性视神经病变(NAION),患者为68岁男性,伴有控制不良的2型糖尿病和明显的远视(+5屈光度)。在开始使用相对高剂量(0.5 mg/周)的semaglutide后14天开始视力丧失,在四周内进展为功能性失明。眼科检查显示双侧视盘水肿伴出血、渗出及视网膜下积液。排除了感染和自身免疫性原因,脑脊液分析正常。在服用高剂量的西马鲁肽后,糖化血红蛋白下降,尽管这种下降的幅度和速度应该谨慎解释,并且药物与视神经事件之间的联系必须被认为是纯粹暂时的,没有直接因果关系的证据。尽管停药和皮质类固醇治疗,视力仍持续下降。同时双侧表现,快速进展和易感解剖因素-视盘拥挤和可能的巩膜刚性-突出了极端易感性。该病例说明了可能的时间关联,代表了迄今为止报道的少数此类病例之一,并强调了基线眼科评估,密切监测和仔细考虑GLP-1受体激动剂治疗患者初始剂量的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
109
审稿时长
78 days
期刊介绍: La revista Archivos de la Sociedad Española de Oftalmología, editada mensualmente por la propia Sociedad, tiene como objetivo publicar trabajos de investigación básica y clínica como artículos originales; casos clínicos, innovaciones técnicas y correlaciones clinicopatológicas en forma de comunicaciones cortas; editoriales; revisiones; cartas al editor; comentarios de libros; información de eventos; noticias personales y anuncios comerciales, así como trabajos de temas históricos y motivos inconográficos relacionados con la Oftalmología. El título abreviado es Arch Soc Esp Oftalmol, y debe ser utilizado en bibliografías, notas a pie de página y referencias bibliográficas.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书